Filter by
Format
All
Sort by
Newest

Metabolic

  • Empagliflozin
  • Linagliptin
/my/metabolic/empagliflozin/when-time-meets-power/tmp-25-years-possibilities

00:00
Series 1 Video
/my/metabolic/empagliflozin/cv-risk-protection/ero-post-hoc-analysis-time-benefit

ERO post hoc analysis - time to benefit
/my/metabolic/empagliflozin/cv-risk-protection/ero-post-hoc-analysis-jardiance-delays-insulin

ERO post hoc analysis - Jardiance delays insulin initiation
/my/metabolic/empagliflozin/experts-interview/why-metformin-still-widely-recommended-and-utilized

6:06
Why is metformin still widely recommended and utilized as first-line T2D agent?
/my/metabolic/empagliflozin/experts-interview/how-do-you-determine-appropriate-hba1c-target-patients

2:39
How do you determine the appropriate HbA1c target for patients with cardiovascular disease?
/my/metabolic/empagliflozin/experts-interview/which-effect-sglt2i-shown-cvots-isisnot-class-effect

2:57
Which effect of SGLT2i shown in CVOTs is/isn’t a class effect and why?
/my/metabolic/empagliflozin/experts-interview/does-benefit-empagliflozin-be-limited-only-high-risk

5:34
Does the benefit of empagliflozin be limited to only high-risk and very-high-risk T2D patients?
/my/metabolic/empagliflozin/webinar/summary-hope-journey-towards-empa-reg-outcome

04:22
SUMMARY- Before hope: A journey towards EMPA-REG OUTCOME
/my/metabolic/empagliflozin/webinar/hope-journey-towards-empa-reg-outcome

27:31
Before hope: A journey towards EMPA-REG OUTCOME
/my/metabolic/empagliflozin/cv-risk-protection/emprise®-new-data-release-ada-congress-2020

EMPRISE® New Data Release in ADA Congress 2020
/my/metabolic/empagliflozin/cv-risk-protection/how-did-empagliflozin-kick-start-transformation

How did empagliflozin kick-start the transformation of guidelines?
/my/metabolic/empagliflozin/cv-risk-protection/how-did-empagliflozin-kick-start

How Did Empagliflozin Kick-Start the Transformation of Guidelines?
/my/metabolic/empagliflozin/cv-risk-protection/empagliflozin-cardiovascular-benefits-lead

Empagliflozin's cardiovascular benefits lead the change in T2D treatment paradigm
/my/metabolic/empagliflozin/cv-risk-protection/empa-reg-outcome-breakthrough-trial-type-2-diabetes

EMPA-REG OUTCOME: A breakthrough trial in type 2 diabetes
/my/metabolic/empagliflozin/cv-risk-protection/emprise-empagliflozin-real-world

EMPRISE - Empagliflozin Real World Effectiveness
/my/metabolic/empagliflozin/experts-interview/asian-forum-2018-how-have-recent-cv-outcome-trials-transcript

Asian CardioDiabetes Forum 2018 - How have recent CV outcome trials influence clinical practice by Dr. Neale Cohen (transcript)
/my/metabolic/empagliflozin/experts-interview/asian-forum-2018-how-have-recent-cv-outcome-trials

03:48
Asian CardioDiabetes Forum 2018 - How have recent CV outcome trials influence clinical practice by Dr. Neale Cohen
/my/metabolic/empagliflozin/experts-interview/asian-forum-2018-role-cardiologist-transcript

Asian CardioDiabetes Forum 2018 - The role of a cardiologist in diabetes management by Dr. Mansoor Husain (transcript)
/my/metabolic/empagliflozin/experts-interview/asian-forum-2018-role-cardiologist

03:51
Asian CardioDiabetes Forum 2018 - The role of a cardiologist in diabetes management by Dr. Mansoor Husain
/my/metabolic/empagliflozin/experts-interview/asian-forum-2018-why-it-important-examine-evidence-transcript

Asian CardioDiabetes Forum 2018 - Why is it important to examine evidence and not assume class effect by Prof. Richard Donnelly (transcript)
/my/metabolic/empagliflozin/experts-interview/asian-forum-2018-why-it-important-examine-evidence

02:28
Asian CardioDiabetes Forum 2018 - Why is it important to examine evidence and not assume class effect by Prof. Richard Donnelly
/my/metabolic/empagliflozin/prescribing-information/jardiance-duo-prescribing-information

Jardiance Duo® Prescribing Information
/my/metabolic/empagliflozin/cv-risk-protection/jardiance-reduces-risk-cv-death-top-standard-care

02:53
Reduction in CV death
/my/metabolic/empagliflozin/cv-risk-protection/what-are-main-considerations-when-choosing-medication

02:34
What are the main considerations when choosing a medication for patients with type 2 diabetes?
/my/metabolic/empagliflozin/cv-risk-protection/are-patients-t2d-elevated-cv-risk

02:10
Are patients with T2D at elevated CV risk?
/my/metabolic/linagliptin/carmelina/carmelina-trial-2020

00:00
CARMELINA Trial 2020
/my/metabolic/linagliptin/efficacy/trajenta-benefits-proven-efficacy-ease-use-one

00:44
Trajenta® benefits: Proven efficacy, ease of use
/my/metabolic/linagliptin/prescribing-information/trajenta-duo-prescribing-information

Linagliptin + Metformin HCl (Trajenta Duo®) Prescribing Information
/my/metabolic/linagliptin/prescribing-information/trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information
/my/metabolic/linagliptin/dosing/simplicity-trajenta-within-dpp4i-class

01:05
Simplicity of Trajenta® within the DPP4i class: Established efficacy, established safety profile, and convenience of one dose once daily
/my/metabolic/linagliptin/dosing/trajenta-makes-life-easier-gps-well-patients

00:56
Trajenta® makes life easier for GPs as well as patients
/my/metabolic/linagliptin/dosing/trajenta-simple-way-keep-your-patients-licensed

01:03
Trajenta®: A simple way to keep your patients on a licensed dose when administered as appropriate: 5 mg OD

Cardiovascular

  • Dabigatran etexilate
  • Telmisartan
/my/cardiovascular/dabigatran-etexilate/safety/life-happens-football-fan

01:44
Life Happens - Football fan
/my/cardiovascular/dabigatran-etexilate/safety/life-happens-fisherman

01:35
Life Happens - Fisherman
/my/cardiovascular/dabigatran-etexilate/safety/life-happens-artist

01:43
Life Happens - Artist
/my/cardiovascular/dabigatran-etexilate/safety/professor-john-eikelboom-dabigatran-patients

03:22
Professor John Eikelboom on dabigatran patients with cardiovascular comorbidities
/my/cardiovascular/dabigatran-etexilate/safety/pradaxa-patient-journey

01:43
Pradaxa patient journey
/my/cardiovascular/dabigatran-etexilate/reversibility/doctors-testimonial

03:40
Doctor's testimonial
/my/cardiovascular/dabigatran-etexilate/safety/patients-testimonial

02:54
Patient's testimonial
/my/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-trial-results

RE-DUAL PCI™ trial - Results
/my/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-2-pci

03:07
RE-DUAL PCI subgroup - Expert Q&As part 2 - PCI complexity
/my/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-2-landmark

04:07
RE-DUAL PCI subgroup - Expert Q&As part 2 - Landmark analysis
/my/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-2-age

03:15
RE-DUAL PCI subgroup - Expert Q&As part 2 - Age
/my/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-1-q3

02:09
RE-DUAL PCI subgroup - Expert Q&As part 1 ACS Q3
/my/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-1-q2

01:36
RE-DUAL PCI subgroup - Expert Q&As part 1 ACS Q2
/my/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subgroup-expert-q-and-a-part-1-q1

02:46
RE-DUAL PCI subgroup - Expert Q&As part 1 ACS Q1
/my/cardiovascular/dabigatran-etexilate/events/air-forum

2:09:22
On Air Forum (13.6.2020)
/my/cardiovascular/dabigatran-etexilate/reversibility/life-happens-pc-my-100938

01:43
Life Happens
/my/cardiovascular/dabigatran-etexilate/reversibility/life-happens-pc-my-100937

01:42
Life Happens
/my/cardiovascular/dabigatran-etexilate/reversibility/life-happens-pc-my-100936

01:43
Life Happens
/my/cardiovascular/dabigatran-etexilate/safety/atrial-fibrillation

04:32
Atrial Fibrillation
/my/cardiovascular/dabigatran-etexilate/reversibility/life-happens-100687

03:29
Life Happens
/my/cardiovascular/dabigatran-etexilate/reversibility/life-happens-100806

01:25
Life Happens
/my/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-praxbind

Prescribing Information for Praxbind®
/my/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-pradaxa

Prescribing Information for Pradaxa®
/my/cardiovascular/dabigatran-etexilate/safety/importance-rwes-complementing-rcts-todd-c-villines

03:39
The Importance of RWEs in Complementing RCTs (By Todd C. Villines)
/my/cardiovascular/dabigatran-etexilate/reversibility/life-happens-aortic-dissection

02:21
Life Happens: Aortic Dissection
/my/cardiovascular/telmisartan/events/air-forum-1172020

00:00
On Air Forum (11.7.2020)
/my/cardiovascular/telmisartan/prescribing-information/telmisartan-amlopidine-twynsta-prescribing

Telmisartan + Amlopidine (Twynsta®) Prescribing Information
/my/cardiovascular/telmisartan/prescribing-information/telmisartan-hctz-micardis-plus-prescribing

Telmisartan + HCTZ (Micardis Plus®) Prescribing Information
/my/cardiovascular/telmisartan/prescribing-information/telmisartan-micardis-prescribing-information

Telmisartan (Micardis®) Prescribing Information
/my/cardiovascular/telmisartan/organ-protection/twynsta-micardis-inside-effective-against-progression

Twynsta, with Micardis inside, is effective against progression of renal disease in hypertensive patients with type 2 diabetes
/my/cardiovascular/telmisartan/blood-pressure-control/blood-pressure-control-view-prof-bryan-william

07:56
Blood Pressure Control: view of Prof Bryan William

Oncology

  • Afatinib
/my/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive

Publication: GioTag Final Analysis
/my/oncology/giotrif/efficacy/giotrif-delays-onset-risk-cns-progression

GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases
/my/oncology/giotrif/efficacy/giotrif-vs-gefitinib-1st-line-treatment-egfrm-nsclc

GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
/my/oncology/giotrif/efficacy/giotrif-provides-3-years-long-term-response

GIOTRIF® provides ≥3 years long-term response even with dose modification
/my/oncology/giotrif/safety/xerosis-management

AE management in focus: Xerosis
/my/oncology/giotrif/safety/stomatitis-management

AE management in focus: Stomatitis
/my/oncology/giotrif/safety/scalp-lesion-management

AE management in focus: Scalp lesion
/my/oncology/giotrif/safety/strategies-optimise-management-egfr-tki-related-side-effects

Strategies to optimise the management of EGFR  TKI-related side effects
/my/oncology/giotrif/efficacy/giotrif-efficacy-and-safety-elderly

Giotrif® efficacy and safety in elderly EGFRm+ NSCLC patients
/my/oncology/giotrif/efficacy/real-world-evidence-giotrif-efficacy

Real-world evidence: GIOTRIF® efficacy in Taiwan and Korea
/my/oncology/giotrif/efficacy/pre-clinical-and-clinical-activity-giotrif

Pre-clinical and clinical activity of GIOTRIF® in uncommon EGFR mutations
/my/oncology/giotrif/safety/ae-management-focus-diarrhoea

AE management in focus: Diarrhoea
/my/oncology/giotrif/safety/ae-management-focus-paronychia

AE management in focus: Paronychia
/my/oncology/giotrif/safety/ae-management-focus-skin-rash

AE management in focus: Skin Rash
/my/oncology/giotrif/dosing-and-administration/giotrif-maintains-efficacy-despite

GIOTRIF® maintains efficacy despite dose modification
/my/oncology/giotrif/sequencing/sequential-treatment-afatinib

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study
/my/oncology/giotrif/sequencing/giotag-real-world-global-study

02:19
GioTag: First real-world global study addressing EGFR  TKI sequencing in routine practice
/my/oncology/giotrif/sequencing/optimising-outcomes

01:27
Optimising outcomes on EGFR M+ NSCLC: Which TKI and when?
/my/oncology/giotrif/efficacy/south-korea-real-world-data

Real-world evidence: GIOTRIF® in South Korea
/my/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information

Respiratory

  • Tiotropium + Olodaterol
/my/respiratory/spiolto/respimat/respimat-delivers-drug-actively

03:29
Respimat delivers drug actively without the need of COPD patients to forcefully inhale
/my/respiratory/spiolto/guidelines/gold-2019-role-lama-laba

01:49
GOLD 2019 - Role of LAMA/LABA
/my/respiratory/spiolto/guidelines/gold-update-2019

08:30
GOLD Update 2019
/my/respiratory/spiolto/tovito/tovito-phase-iii-clinical-trial-programme

TOVITO® Clinical Trial Programme
/my/respiratory/spiolto/respimat/importance-particle-size

01:17
Respimat® produces a soft mist of high fine particle fraction aerosol which delivers Spiolto® deep into patients' lungs
/my/respiratory/spiolto/respimat/how-assemble

01:23
Respimat® Device Assembly - Preparation for First Use
/my/respiratory/spiolto/respimat/how-use

00:51
Preparing Respimat® for Daily Use
/my/respiratory/spiolto/efficacy/treatment-lamalaba-vs-lamalabaics

02:02
WISDOM trial suggests only a minority of COPD patients benefit from the addition of an ICS on top of SPIRIVA+LABA, and these are clearly identifiable
/my/respiratory/spiolto/efficacy/treatment-lamalaba-vs-labaics

01:35
ENERGITO and FLAME demonstrate consistent superiority with LAMA/LABA vs LABA/ICS for all outcomes related to lung function, symptom control and exacerbations
/my/respiratory/spiolto/efficacy/early-intervention-optimize-lung-function

02:13
Early intervention to optimize lung function
/my/respiratory/spiolto/prescribing-information

Spiolto® Respimat® Prescribing Information